Markel launches Clinical Trials products to support clinical trials research, globally
Markel Insurance (NYSE: MKL) has launched a new Clinical Trials insurance product designed to provide comprehensive coverage for sponsors, researchers, and participants across all phases of clinical research. The product offers coverage in over 100 territories and features same-day quotation turnaround along with automated document production for certificates and policies.
Key features include Lloyd's licenses utilization, an extensive global network for compliant solutions, and expert underwriting backed by award-winning claims service. The offering aims to streamline the insurance process, which is often the final regulatory requirement before clinical trials can begin, helping avoid costly delays and research suspensions.
Markel Insurance (NYSE: MKL) ha lanciato un nuovo prodotto assicurativo per studi clinici progettato per offrire una copertura completa a sponsor, ricercatori e partecipanti in tutte le fasi della ricerca clinica. Il prodotto è disponibile in oltre 100 territori e garantisce preventivi nello stesso giorno, oltre a una produzione automatizzata di documenti per certificati e polizze.
Le caratteristiche principali includono l'utilizzo delle licenze Lloyd's, una vasta rete globale per soluzioni conformi e una sottoscrizione esperta supportata da un servizio sinistri premiato. L'offerta mira a semplificare il processo assicurativo, spesso l'ultimo requisito normativo prima dell'inizio degli studi clinici, aiutando a evitare ritardi costosi e sospensioni della ricerca.
Markel Insurance (NYSE: MKL) ha lanzado un nuevo producto de seguro para ensayos clínicos diseñado para brindar una cobertura integral a patrocinadores, investigadores y participantes en todas las fases de la investigación clínica. El producto ofrece cobertura en más de 100 territorios y cuenta con cotizaciones el mismo día junto con la producción automatizada de documentos para certificados y pólizas.
Las características clave incluyen la utilización de licencias de Lloyd's, una amplia red global para soluciones conformes y una suscripción experta respaldada por un servicio de reclamaciones galardonado. La oferta busca agilizar el proceso de seguro, que a menudo es el último requisito regulatorio antes de que comiencen los ensayos clínicos, ayudando a evitar retrasos costosos y suspensiones en la investigación.
Markel Insurance (NYSE: MKL)는 임상 연구의 모든 단계에서 스폰서, 연구원 및 참여자를 위한 포괄적인 보장을 제공하도록 설계된 새로운 임상 시험 보험 상품을 출시했습니다. 이 상품은 100개 이상의 지역에서 보장을 제공하며, 당일 견적 제공과 증명서 및 보험증서 자동 문서 생성 기능을 특징으로 합니다.
주요 특징으로는 로이드 라이선스 활용, 규정을 준수하는 솔루션을 위한 광범위한 글로벌 네트워크, 그리고 수상 경력이 있는 클레임 서비스가 뒷받침하는 전문 인수 심사가 포함됩니다. 이 상품은 임상 시험 시작 전에 필요한 마지막 규제 요건인 보험 절차를 간소화하여 비용이 많이 드는 지연과 연구 중단을 방지하는 데 도움을 줍니다.
Markel Insurance (NYSE : MKL) a lancé un nouveau produit d'assurance pour les essais cliniques conçu pour offrir une couverture complète aux sponsors, chercheurs et participants à toutes les phases de la recherche clinique. Ce produit propose une couverture dans plus de 100 territoires et offre une réponse de devis le jour même ainsi qu'une production automatisée des documents pour certificats et polices.
Les principales caractéristiques incluent l'utilisation des licences Lloyd's, un vaste réseau mondial pour des solutions conformes, et une souscription experte soutenue par un service de gestion des sinistres primé. Cette offre vise à simplifier le processus d'assurance, souvent la dernière exigence réglementaire avant le début des essais cliniques, aidant ainsi à éviter des retards coûteux et des suspensions de recherche.
Markel Insurance (NYSE: MKL) hat ein neues Versicherungsprodukt für klinische Studien eingeführt, das umfassenden Schutz für Sponsoren, Forscher und Teilnehmer in allen Phasen der klinischen Forschung bietet. Das Produkt deckt über 100 Gebiete ab und bietet eine Angebotsabgabe am selben Tag sowie eine automatisierte Dokumentenerstellung für Zertifikate und Policen.
Zu den Hauptmerkmalen zählen die Nutzung von Lloyd's-Lizenzen, ein umfangreiches globales Netzwerk für konforme Lösungen und eine fachkundige Underwriting-Unterstützung, die durch einen preisgekrönten Schadenservice gestützt wird. Das Angebot zielt darauf ab, den Versicherungsprozess zu vereinfachen, der oft die letzte regulatorische Anforderung vor Beginn klinischer Studien darstellt, und so kostspielige Verzögerungen und Forschungsaussetzungen zu vermeiden.
- Launch of new comprehensive Clinical Trials insurance product covering over 100 territories
- Same-day turnaround for quotations and automated document processing
- Potential for new revenue stream in the growing clinical trials sector
- Leveraging existing Lloyd's licenses and global network for expanded market reach
- None.
Insights
Markel's new Clinical Trials insurance offering expands their specialty product line while addressing service pain points in a regulated market.
Markel's launch of a dedicated Clinical Trials insurance product represents a strategic expansion of their specialty insurance portfolio. The company has developed a solution tailored to meet a critical regulatory requirement that clinical trial sponsors must satisfy before commencing research in numerous jurisdictions worldwide.
The product differentiates itself through three key features: comprehensive coverage spanning all clinical trial phases, global compliance capabilities across over 100 territories, and same-day turnaround for quotations and document issuance. This expedited service directly addresses a significant industry pain point—insurance delays that can postpone vital research, increase costs, and potentially damage reputations.
By leveraging their Lloyd's licenses and existing global network, Markel is utilizing established infrastructure to deliver this specialized offering efficiently. The emphasis on streamlined processes and rapid documentation demonstrates an operational focus on service delivery in a time-sensitive market.
Clinical trials represent a critical component of medical innovation, and by positioning themselves as facilitators rather than bottlenecks in this process, Markel is aligning with the needs of life science companies conducting global research. The product appears designed to remove administrative friction from an already complex regulatory approval process.
While this launch represents a logical extension of Markel's specialty insurance operations, the announcement doesn't provide financial projections or market sizing information to quantify its potential impact on overall company performance.
The new clinical trials offering provides comprehensive cover to sponsors, researchers and participants throughout all phases of clinical research and is tailored to meet the regulatory requirements of more than 100 territories, ensuring smooth and compliant trial operations, worldwide.
As part of its service offering, Markel can offer same-day turnaround for quotations, as well as the issuance of certificates and policy documents through its automated document production platform, so that clinical trial sponsors and researchers can get the required insurance in place to begin clinical trials in a timely manner and meet regulatory deadlines. Markel utilises its Lloyd's licenses and extensive global network to provide these solutions to ensure a compliant solution where required.
"Clinical trials insurance is a regulatory requirement in many countries and it's often the last hurdle to get approval to begin clinical research," says Robert Hannaford, Senior Underwriter – Life Science, Markel. "Delays to this process can result in sizeable costs, reputational damage and suspend vital research from going ahead for sponsors and researchers.
"At Markel, we understand the time-sensitive nature of these requests and have developed a compliant solution – backed by our expert underwriting and award-winning claims service, making sure clients are fully protected to carry out the clinical research of products worldwide."
Hannaford continues: "We do not want insurance to be a delaying factor to allowing important clinical research to begin, which is why we've produced a customer-centric product that streamlines all parts of the insurance value chain to prioritise service.
"We look forward to supporting innovation in the life science industry by continuing to deliver effective risk transfer solutions for future lifesaving treatments through open communication, dialogue and transparency with our brokers, insureds and trading partners."
About Markel Insurance
We are Markel Insurance, a leading global specialty insurer with a truly people-first approach. As the insurance operations within the Markel Group Inc. (NYSE: MKL), we leverage a broad array of capabilities and expertise to create intelligent solutions for the most complex specialty insurance needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/markel-launches-clinical-trials-products-to-support-clinical-trials-research-globally-302445849.html
SOURCE Markel
FAQ
What is Markel's (MKL) new Clinical Trials insurance product?
How fast can Markel (MKL) process Clinical Trials insurance applications?
What territories does Markel's (MKL) Clinical Trials insurance cover?
What features are included in Markel's (MKL) Clinical Trials insurance?
